Related Experiment Video
Updated: Oct 15, 2025
09:41
Formulating and Characterizing Lipid Nanoparticles for Gene Delivery using a Microfluidic Mixing Platform
Published on: February 25, 2021
24.0K
Major difference in particle size, minor difference in release profile: a case study of solid lipid nanoparticles
Zhengwei Huang1, Linjing Wu1, Wenhao Wang2
1College of Pharmacy, Jinan University, Guangzhou, China.
Pharmaceutical Development and Technology
|October 25, 2021
Summary
Solid lipid nanoparticles (SLN) particle size influences drug release, though the correlation is weak with broad size distributions. This research offers insights into SLN in vitro release for nanomedicine development.
Area of Science:
- Nanotechnology
- Pharmaceutical Sciences
- Materials Science
Background:
- Solid lipid nanoparticles (SLN) are advanced drug delivery systems known for controlled release.
- Particle size is a key factor influencing the drug release kinetics of SLN.
- Understanding the relationship between SLN particle size and drug release is crucial for optimizing nanomedicine formulations.
Purpose of the Study:
- To investigate the correlation between the particle size of solid lipid nanoparticles (SLN) and their in vitro drug release profiles.
- To synthesize budesonide-loaded SLN with varying particle sizes using hot high-pressure homogenization.
- To evaluate the influence of particle size distribution on drug release behavior.
Main Methods:
- Synthesis of budesonide-loaded solid lipid nanoparticles (BUD-SLN) using hot high-pressure homogenization (HPH).
- Characterization of BUD-SLN for particle size (120-480 nm), encapsulation efficiency, drug loading, and stability.
- In vitro drug release studies in Tris-Maleate media with and without pancreatin or ethanol.
- Analysis of drug release kinetics using models like Ritger-Peppas and first-order kinetics.
Main Results:
- Prepared BUD-SLN exhibited good encapsulation efficiency, drug loading, and stability.
- In vitro release was negligible in Tris-Maleate buffer alone.
- Drug release kinetics followed the Ritger-Peppas model in Tris-Maleate plus pancreatin and first-order kinetics in Tris-Maleate-ethanol.
- A weak, insignificant correlation was observed between average particle size and release behavior when particle size distribution was broad.
Conclusions:
- The particle size of SLN has a limited impact on drug release, especially when particle size distribution is wide.
- Drug release from SLN is dependent on the composition of the release medium.
- This study provides valuable insights for the rational design and development of novel nanomedicines utilizing SLN technology.
Related Concept Videos
01:23Factors Affecting Dissolution: Particle Size and Effective Surface Area
1.1K
Dissolution kinetics, an essential aspect of oral drug delivery, is significantly influenced by the drug's particle size. According to the Noyes-Whitney dissolution model, the dissolution rate correlates directly with the drug's surface area. The larger the surface area, the higher the drug's solubility in water, leading to a faster drug dissolution rate. Reducing particle size increases the effective surface area, enhancing the dissolution process. Micronization and nanosizing are...
1.1K
01:27Pharmaceutical Alternatives: Polymorphic Form-Related and Particle Size-Related Therapeutic Nonequivalence
15
Changes in polymorphic forms can significantly influence the bioavailability of poorly soluble drugs. Although the FDA defines pharmaceutical equivalence based on having the same active ingredient, dosage form, and route of administration, it does not automatically disqualify products with different polymorphic forms. This means two products with different polymorphs can still be deemed pharmaceutically equivalent. However, polymorphic differences can affect properties like wettability,...
15
01:14Drug Dissolution: Requirements and Profile Comparison
38
The acceptance criteria for dissolution profile data are anchored in Q values, representing the percentage of drug dissolved within a specified period. This assessment unfolds in three stages:First Stage: The test passes if all six drug dosage units are equal to or greater than Q plus 5%; otherwise, the sample proceeds to the second stage.Second Stage: The average of twelve units must be equal to or greater than Q, with no unit falling below Q - 15% to pass; if not, it progresses to the final...
38
01:16Bioavailability Enhancement: Drug Solubility Enhancement
13
Body:Bioavailability is a critical factor in determining a drug's effectiveness. It refers to the proportion of a drug that enters the circulation when introduced into the body and is, as a result, able to have an active effect. Enhancing bioavailability is essential for drugs with poor solubility, as it can significantly impact their therapeutic efficacy. Various methods are employed to increase the solubility of drugs, thereby enhancing their bioavailability.Micronization and nanonization are...
13